Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in Renmark Financial Communications' virtual non-deal roadshow on October 20, 2026. CEO and Chairman Robert Bitterman will present at 12:00 PM EDT, followed by a live question-and-answer session. The presentation will cover the company's INTASYL gene-silencing therapeutic platform and its lead clinical candidate, PH-762, for treating cutaneous carcinomas, or skin cancers.
Phio Pharmaceuticals (PHIO) has released its first commercial-scale batch of PH-762 drug substance, completing a manufacturing milestone for its cancer treatment program.
The active pharmaceutical ingredient met established specifications and quality requirements and was manufactured under current Good Manufacturing Practice (cGMP) regulations. It will now undergo final drug product completion steps for use in the planned Phase 2b study. Phio plans to initiate that trial in the first quarter of 2027 and said the manufacturing milestone supports supply chain readiness and its potential commercialization strategy.
Phio Pharmaceuticals (NASDAQ: PHIO) will present its cancer therapeutic platform at The Global Markets Virtual Forum on October 8, 2026. President and Chief Executive Officer Robert Bitterman will speak at 12:40 PM EDT, covering the INTASYL siRNA gene-silencing platform, its delivery approach and the company's direction.
The online event allows investors to ask questions in real time. An archived webcast will be available afterward. Bitterman will also be available for one-on-one meetings on October 8, 9 and 12, 2026.
Phio Pharmaceuticals (NASDAQ: PHIO) will present its therapeutic platform and PH-762 development update at NIBA's 153rd Conference on October 7, 2026. CEO Robert Bitterman's presentation is scheduled for 12:40 PM EDT at The Westin Fort Lauderdale Beach Resort. PH-762 is its lead clinical-stage program in cutaneous squamous cell carcinoma, a skin cancer. Bitterman and CFO Lisa Carson will attend the October 6–7 conference and be available for one-on-one meetings.
Phio Pharmaceuticals (PHIO) will present a clinical development update on its lead INTASYL-based candidate PH-762 at the Life Sciences Future 2026 Conference on September 30, 2026.
President and CEO Robert Bitterman will discuss the completed Phase 1b study of PH-762 in cutaneous squamous cell carcinoma and outline planned next steps to advance the program to its next stage of clinical development. The company plans to build on the favorable safety profile seen in Phase 1b and will review upcoming clinical, regulatory, and development objectives for PH-762. The presentation is scheduled for 10:20 AM (ET) at the Sheraton Valley Forge Hotel in King of Prussia, Pennsylvania, with management also available for one-on-one meetings.
Phio Pharmaceuticals (PHIO) has submitted a meeting request and comprehensive briefing package to the U.S. FDA to support the next stage of clinical development for its INTASYL siRNA candidate PH-762 in cutaneous squamous cell carcinoma.
The package summarizes the nonclinical development program, integrated clinical pharmacology data, and results from the completed Phase 1b study, and outlines the proposed Phase 2b neoadjuvant trial, including its scientific rationale, study design, and pharmacokinetic strategy. Phio’s CEO described the FDA submission as a key achievement for the PH-762 program and an important step toward realizing its clinical potential. The company is preparing to manufacture clinical supplies for the planned Phase 2b study, which are expected to be available in the first quarter of 2027. Phio also reports completion of the dosing phase of its nonclinical toxicology study, with remaining activities supporting the next clinical phase expected to be finished in the first quarter of 2027.
Phio Pharmaceuticals (PHIO)/b) will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.President and CEO Robert Bitterman and CFO Lisa Carson will hold one-on-one meetings with investors and discuss the clinical lead candidate PH-762, strategic priorities, and upcoming initiatives. A webcast of the company’s presentation will be accessible via an online link. PH-762, based on Phio’s INTASYL siRNA gene-silencing technology, targets the PD-1 gene and is being evaluated as a potential non-surgical treatment for several skin cancers.
Phio Pharmaceuticals (NASDAQ: PHIO) announced a U.S. Notice of Allowance for a patent covering PH-894, an INTASYL-based compound designed to selectively silence the BRD4 protein, a regulator of gene expression linked to proliferative and infectious diseases. The patent provides protection for PH-894’s chemical structure, genetic sequencing and broad therapeutic applications in the U.S.
According to Phio Pharmaceuticals, this allowance is a key milestone that strengthens its INTASYL intellectual property portfolio, which now includes 54 issued patents globally covering INTASYL chemistry, gene targets, immuno-oncology compounds and therapeutic uses. The company states this supports advancing PH-894 in the U.S. and pursuing strategic international collaborations.
Phio Pharmaceuticals (NASDAQ: PHIO) reported second quarter 2026 results and a business update focused on lead siRNA candidate PH-762. The company completed a 22-patient U.S. Phase 1b trial in skin cancers, is finalizing comprehensive study documentation for FDA submission, and plans to request an FDA meeting in Q3 2026 on next‑step trial design.
Phio initiated commercial-scale PH-762 API manufacturing and a long-term non-clinical toxicology study, both expected to finish by year-end, and reported new intellectual property actions, including three notices of allowance and one patent grant in the United States, Canada and Japan. Cash and cash equivalents were $13.0 million at June 30, 2026 versus $21.0 million at year-end 2025, with funding runway expected into the second half of 2027. Q2 2026 research and development expenses rose to $3.1 million (up 187% year-over-year), general and administrative expenses were $1.2 million, and net loss widened to $4.1 million from $2.2 million a year earlier. In April 2026, Phio established a $6.36 million at-the-market equity offering program and appointed dermatologist and former FDA advisory committee member Dr. R. Todd Plott to its Board of Directors.
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series on Tuesday, July 28, 2026, at 12 PM EDT. CEO and Chairman Robert Bitterman will present an overview of the company’s proprietary INTASYL® siRNA gene silencing platform, highlighting lead clinical candidate PH-762 for cutaneous carcinomas, followed by a live Q&A session with investors. This announcement corrects the previously misstated day of the week. A replay may be available on Renmark’s website. Phio describes PH-762, which silences the PD-1 gene, as a potential non-surgical treatment for various skin cancers.